A detailed history of Core Cap Advisors, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Core Cap Advisors, LLC holds 133 shares of FATE stock, worth $356. This represents 0.0% of its overall portfolio holdings.

Number of Shares
133
Holding current value
$356
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$3.12 - $5.57 $414 - $740
133 New
133 $0
Q1 2022

Apr 29, 2022

SELL
$29.67 - $60.28 $4,598 - $9,343
-155 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$47.84 - $64.34 $7,415 - $9,972
155 New
155 $9,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $260M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.